↓ Skip to main content

Dove Medical Press

Article Metrics

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice

Overview of attention for article published in Neuropsychiatric Disease and Treatment, April 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
36 Mendeley
Title
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
Published in
Neuropsychiatric Disease and Treatment, April 2012
DOI 10.2147/ndt.s29116
Pubmed ID
Authors

Stefan Spittler, Seibert, Tracik, Articus

Abstract

Oral cholinesterase inhibitors at doses efficacious for the treatment of Alzheimer's disease (AD) are often prematurely discontinued due to gastrointestinal side effects. In controlled clinical trials, transdermal rivastigmine demonstrated less such effects at similar efficacy. The current study aimed to verify the validity of this data in daily practice.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 28%
Researcher 6 17%
Student > Ph. D. Student 5 14%
Other 3 8%
Student > Bachelor 2 6%
Other 5 14%
Unknown 5 14%
Readers by discipline Count As %
Medicine and Dentistry 9 25%
Psychology 8 22%
Biochemistry, Genetics and Molecular Biology 4 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Nursing and Health Professions 2 6%
Other 5 14%
Unknown 5 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2012.
All research outputs
#3,533,556
of 4,506,935 outputs
Outputs from Neuropsychiatric Disease and Treatment
#764
of 908 outputs
Outputs of similar age
#58,522
of 75,175 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#26
of 31 outputs
Altmetric has tracked 4,506,935 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,175 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.